Stockreport

Blueprint's avapritinib pain is Deciphera's gain, up 16% [Seeking Alpha]

Deciphera Pharmaceuticals, Inc.  (DCPH) 
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: deciphera.com/investor-relations
PDF Deciphera Pharmaceuticals (NASDAQ:DCPH16%unsuccessful resultsDeciphera's lead candidate is ripretinib. Its U.S. application for GIST is currently under FDA review with a [Read more]